Navigation Links
PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
Date:1/15/2014

nes as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting India Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 112.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 143.2 Symptoms 184 Disease Management 204.1 Diagnosis 204.2 Treatment Overview 224.3 India 284.3.1 Diagnosis 284.3.2 Clinical Practice 305 Competitive Assessment 315.1 Overview 315.2 Strategic Competitor Assessment 325.3 Product Profiles - Major Brands 335.3.1 Protopic (tacrolimus) 335.3.2 Elidel 405.3.3 Cyclosporine (numerous generic names) 465.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 496 Opportunity and Unmet Need 516.1 Overview 516.2 Unmet Needs 526.2.1 A Systemic Drug for Severe Recalcitrant Patients 526.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 546.2.3 A Drug that Effectively Controls Patients' Pruritus 556.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 566.2.5 A Drug t
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Alzheimers Disease - China Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
10. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
11. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher ... Compared to Standard ... and MTA: CTIC) announced today that it achieved the primary,efficacy ... for patients with advanced, relapsed aggressive non-Hodgkin,s,lymphoma (NHL) based on ...
... PRINCETON, N.J., Nov. 10 Pharmasset, Inc.,(Nasdaq: VRUS ... ITMN ) today,announced that the first patients have been ... with the hepatitis C virus (HCV).,The trial (run in ... to,investigate the combination of two oral antiviral molecules in ...
Cached Medicine Technology:Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 2Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 3Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 5
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... University researchers have identified an important enzyme pathway that ... too few chromosomes, a condition that has been directly ... associate professor of biochemistry, found that near the end ... enzyme that ensures any breaks in DNA are fully ... genome to daughter cells. This process helps safeguard against ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... April 21, 2014 Five for-profit and non-profit ... $1.25 million in Proof of Concept grants to ... into commercial products, the Life Sciences Discovery Fund ... Entrepreneur Mentoring Program grant to the Washington Biotechnology ... advisory network to train the next generation of ...
(Date:4/23/2014)... as Ritalin, may prevent the depletion of self-control, according ... journal of the Association for Psychological Science. , Self-control ... trying to focus attention on a boring textbook are ... explanation for this difficulty: Exerting self-control for a long ... effectively on subsequent tasks. , "It is as if ...
Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:ADHD drug may help preserve our self-control resources 2
... Will Retire from the Lilly ... Board, ... LLY ) has elected Michael L. Eskew, former,chairman and chief executive officer ... Eskew will stand for election,by the shareholders at the 2008 annual meeting in ...
... Feb. 19 WeissComm Partners,the largest independent ... announced the appointment of Tom Jones as ... Corporation,where he was executive director of communications, ... relations programs for the,company,s growth driver brands. ...
... Nation,s 6th Best Hospital, DENVER, Feb. ... Board: GLOB), an international e-Health, medical,information technology ... has signed an agreement with NewYork-Presbyterian,Hospital (NYP), ... in the,world, to license its SafeTrace Tx(R) ...
... under control, researchers say , , TUESDAY, Feb. 19 (HealthDay ... blood pressure under control, and this may help explain ... pressure. , That,s just one of a series of ... of the journal Hypertension . The issue commemorates ...
... While Cutting Prices for,Existing Drugs, According to a ... Mass., Feb. 19 Decision Resources, Inc., one,of ... on,pharmaceutical and healthcare issues, finds that Japan has ... for 2008 and beyond.,The changes reflect the Japanese ...
... Feb. 19 Arcapita Inc., a leading private,equity investment ... its,affiliates have agreed to sell TLC Health Care Services, ... AMED ), for an enterprise value of,$395 million., ... York, TLC is the,largest privately-held home healthcare provider in ...
Cached Medicine News:Health News:Michael L. Eskew Elected to Lilly Board of Directors 2Health News:WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 3Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 4Health News:Hypertension a Health Challenge for Women 2Health News:Hypertension a Health Challenge for Women 3Health News:Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism 2Health News:Arcapita to Sell TLC Health Care Services, Inc. for $395 Million 2
... Gore's EXCLUDER AAA Endoprosthesis is an ... invasive treatment option for patients with abdominal ... a durable ePTFE bifurcated graft with an ... both device flexibility and material durability. The ...
... remove a cast from an arm or leg ... are cut or burned by the cast saw ... to remove any cast with confidence. This innovative, ... and burns from the cast saw and can ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... Patch utilizes advanced fluoropolymer technology, ... penetrating suture and decrease suture ... as 88 percent. This improvement, ... multi-directional strength and low thrombogenicity, ...
Medicine Products: